当前位置: 首页 > 期刊 > 《中国医学创新》 > 2017年第13期
编号:13052896
MDSC的免疫调节机制及其在免疫治疗中的作用(5)
http://www.100md.com 2017年5月5日 《中国医学创新》 2017年第13期
     [21] De Sanctis F,Solito S,Ugel S,et al.Myeloid-derived suppressor cells in cancer:conceiving new prognostic and therapeutic targets[J].Biochim Biophys Acta,2016,1865(1):35-48.

    [22] Ko J S,Zea A H,Rini B I,et al.Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients[J].Clin Cancer Res,2009,15(6):2148-2157.

    [23] Michels T,Shurin G V,Naiditch H,et al.Paclitaxel promotes differentiation of myeloid-derived suppressor cells into dendritic cells in vitro in TLR4-independent manner[J].J Immunotoxicol,2012,9(3):292-300.

    [24] Sevko A,Michels T,Vrohlings M,et al.Antitumor effect of paclitaxel is Mediated by inhibition of myeloid–derived suppressor cells and chronic inflammation in the spontaneous melanoma model[J].J Immunol,2013,190(5):2464-2471.

    [25] Zollo M,Di Dato V,Spano D,et al.Targeting monocyte chemotactic protein-1 synthesis with bindarit induces tumor regression in prostate and breast cancer animal models[J].Clin Exp Metastasis,2012,29(6):585-601.

    [26] Kalinski P.Regulation of immune responses by prostaglandin E2[J].J Immunol,2012,188(1):21-28.

    (收稿日期:2017-02-22) (本文編辑:程旭然), http://www.100md.com(李诗 杨志刚)
上一页1 2 3 4 5